By Rob Dillard June 2, 2023 A proof-of-concept study indicates the combined use of ruxolitinib and magrolimab is effective in the treatment of myelofibrosis (MF). The results were presented at the 2023 American Society of Clinical Oncology Annual Meeting. “In solid tumors, calreticulin (CALR) overexpression produces a prophagocytic signal and is counteracted by concomitant expression […]

Jun 1, 2023 Conor Killmurray Results from the phase 2 MAJIC-PV study showed that patients with polycythemia vera who are intolerant to hydroxycarbamide chemotherapy had superior efficacy results on ruxolitinib. Patients with polycythemia vera (PV) that are intolerant or resistant to hydroxycarbamide chemotherapy had superior responses with ruxolitinib compared to patients on the best available […]

May 30, 2023 Targeted Oncology Staff In the second part of a live discussion on treating patients with myelofibrosis, Jonathan Abbas, MD, led a talk on the impact of ruxolitinib for these patients and where physicians stand with the use of fedratinib. CASE SUMMARY A 68-year-old woman presented to her physician with symptoms of mild […]

May 19, 2023 Ashling Wahner Treatment with ruxolitinib generated superior responses vs treatment with best available therapy in patients with hydroxycarbamide-intolerant or -resistant polycythemia vera, according to findings from the phase 2 MAJIC-PV trial. Treatment with ruxolitinib (Jakafi) generated superior responses vs treatment with best available therapy (BAT) in patients with hydroxycarbamide-intolerant or -resistant polycythemia […]

Thomas Systchenko, Jean-Claude Chomel, Pilar Gallego-Hernanz, Niels Moya, Déborah Desmier, Natacha Maillard, Arthur Bobin, Mathilde Vonfeld, Hélène Gardeney, Emilie Cayssials E, José Torregrosa First published: 14 May 2023 Summary Myeloproliferative neoplasms in blastic phase (MPN-BP) have a dreadful prognosis. We report the characteristics and outcomes of five MPN-BP patients treated with a never-before-described combination of azacytidine and venetoclax (to control BP transformation), added to ruxolitinib (needed […]

May 9, 2023 Kristi Rosa Enrollment to the phase 3 MANIFEST-2 trial, which is examining the safety and efficacy of pelabresib plus ruxolitinib vs ruxolitinib alone in patients with JAK inhibitor–naïve myelofibrosis, has completed and topline findings are anticipated by the end of 2023. Enrollment to the phase 3 MANIFEST-2 trial (NCT04603495), which is examining […]

Results from a new trial sponsored by the Cancer Research UK Clinical Trials Unit at University of Birmingham have found that ruxolitinib is better for treating patients with polycythaemia vera (PV) than the existing treatments. PV is an incurable blood cancer and part of some conditions that affect the blood called myeloproliferative neoplasms (MPNs). During the Phase […]

Authors: Francesca Palandri, Elena M. Elli, Giuseppe Auteri, Massimiliano Bonifacio, Giulia Benevolo, et al. Blood Cancer Journal  volume 13, Article number: 65 (2023)  Introduction The coronavirus disease 2019 (Covid19) pandemic caused by the spreading of the coronavirus SARS-CoV-2 has led to substantial mortality in patients with hematological diseases [1]. During the first wave of pandemic, patients with Philadelphia-negative chronic […]

Apr 21, 2023 Nichole Tucker Researchers are backing further investigation of 60 mg selinexor plus ruxolitinib based on positive phase 1/2 findings presented at the AACR Annual Meeting 2023. Once-weekly (QW) selinexor administered at 60 mg in combination with ruxolitinib (Jakafi) achieved rapid and deep spleen responses that were sustained, as well as robust symptom […]